-
US Vice President Vance departs for Hungary in support of Orban
-
Ex-top aide of Spanish PM set to go on trial for graft
-
Tokyo confirms Japanese national held by Iran freed
-
AI-generated artists break through in country music
-
Rio de Janeiro's gangs hijack buses to sow chaos in war with police
-
Iran defiant as deadline looms for Trump threat to infrastructure
-
Tiger's treatment battle in thoughts of stars at Masters
-
Thai amateur 'Fifa' ready for Masters kick-off
-
'Hacks' has 'perfect' ending after 5 seasons, says star Smart
-
Age and near misses don't worry Rose in Masters quest
-
'Incredibly dangerous': rescuing downed fighter crew in Iran
-
Wall Street stocks rise on hopes for US-Iran ceasefire
-
High-flying Villarreal stumble at Girona
-
Promoter defends plan for Kanye West to headline London fest
-
Napoli's Serie A title defence boosted by beating AC Milan
-
Trump lashes out at 'paper tiger' NATO while re-upping Greenland claim
-
Reed finds DP World Tour success after leaving LIV
-
Lunar crater named after Artemis commander's deceased wife
-
WNBA star Reese joining Atlanta from Chicago: club
-
Gotterup seeks rare win in Masters debut
-
Bayern's Kompany waiting on Kane for 'toughest' game at Real Madrid
-
Juve beat Genoa to close in on Serie A top four
-
'Historic day': Artemis astronauts break space distance record
-
Augusta already firm and fast ahead of 90th Masters
-
French hope Seixas storms Basque Tour time-trial opener
-
Trump says Iran ceasefire proposal 'very significant step'
-
Wawrinka falls in first round on Monte Carlo farewell
-
Greece PM calls on European prosecutor to act 'without delay' on agriculture fraud
-
US Democratic lawmakers slam 'economic bombing' after Cuba visit
-
Red Cross chief condemns 'deliberate threats' against civilians in Mideast war
-
Giant step for humankind: Artemis crew to set space distance record
-
Wawrinka falls in first round of Monte Carlo Masters
-
Ex-England rugby international Lawes to leave Brive
-
Fit-again Mbappe at Real Madrid for clashes like Bayern tie: Arbeloa
-
Swimmers McKeown, O'Callaghan and Chalmers dominate at Australian Open
-
Bucha: When the Russian killers came...
-
Iran, a Terrorist State with No Right to Exist
-
African players in Europe: Semenyo scores as City rout Liverpool
-
Israeli strikes kill Iran Guards intel chief as Trump deadline looms
-
Saving energy in everyday life or a complete rip-off?
-
US sprint star Richardson wins Australia's Stawell Gift in record time
-
Rockets down Warriors in Curry return, Flagg carries Mavs past Lakers
-
Artemis mission approaches lunar loop for first flyby since 1972
-
Israeli rescuers search for missing in building strike, two dead
-
Defiant Iran ramps up attacks after Trump warning
-
Saudi oasis town adjusts to life in the firing line
-
Pogacar stays humble with Monument history beckoning
-
Real Madrid hoping Champions League magic halts Bayern juggernaut
-
Sputtering Arsenal face test of character in Sporting clash
-
'Not the Cairo we know': Energy shock from Iran war dims Egypt nights
PromiCell, Inc. presents during JP Morgan's 2026 Healthcare Conference
MIAMI, FL / ACCESS Newswire / January 9, 2026 / PromiCell, Inc. (the "Company"), a clinical-stage cellular immunotherapy company uniquely positioned to advance potentially curative cell therapies for cancer patients, today announced that the Company's Chief Medical Officer, John Lee, MD, Ph.D., will present interim results of the Company's lead asset PRO CAR - 201A, a STEAP1 directed CAR T cell that is currently in the clinic as a first-in-human phase 1 trial for the treatment of metastatic castration-resistant prostate cancer (mCRPC), at Biotech Showcase 2026 in San Francisco, California on Monday, January 12, 2025 at 11:15 am PST at the Franciscan D (Ballroom Level).
About PromiCell, Inc.
PromiCell, is a clinical-stage cellular immunotherapy company with product candidates representing highly differentiated and novel CAR T and TCR T platforms to be developed across separate solid and hematologic types of cancer. Our pipeline of innovative products includes STEAP 1 CAR T cells, HA-1 TCR T cells and CD 33 CAR T cells, applicable for the treatment of patients with mCRPC, Ewing Sarcoma, recurrent leukemia and acute myeloid leukemia. Our next-generation chimeric antigen receptor CAR T cell therapies are designed to address key mechanisms of tumor escape, disease relapse, and immune evasion. Our scientists are pioneers in CAR T-cell therapy, united in a mission to outsmart cancer and deliver more cures for patients. Learn more at www.promicell.com.
Contact:
305-433-1287
[email protected]
SOURCE: Promicell
View the original press release on ACCESS Newswire
M.White--AT